Navigation Links
Does the existing standard of care supply energy sources to brain tumor cells?
Date:7/14/2010

Chestnut Hill, Mass. (7/14/2010) The medical standard of care comprised of surgery, radiation and chemotherapy for the most common form of brain cancer triggers a number of biological responses that may actually feed the energy metabolism that supports the disease, according to Boston College researchers writing in the journal Lancet Oncology.

The deadly glioblastoma multiforme leaves the average patient a median survival of about a year from diagnosis. Just three percent of patients afflicted with the fast-moving brain cancer survive 36 months. The standard of care for the treatment of the disease has not changed markedly since it was established 50 years ago.

But the effects of surgery, radiation and chemotherapy produce a range of biochemical responses in the brain that can fuel tumor cell survival at the same time doctors are attempting to eradicate the disease, according to Boston College Professor of Biology Thomas Seyfried, whose lab has researched ways to deny energy to cancer cells.

"All tumors, regardless of where they are located, require two major fuels for survival: glucose and glutamine," said Seyfried, a specialist in lipid biochemistry. "As long as tumor cells have access to these energy molecules, they will survive. If you give them a lot of these molecules, they will survive even better."

The three components of cerebral cancer care may play a role in providing tumor cells with the metabolic fuels they need to survive. While these treatments reduce tumor growth over the short term, radiation and certain chemotherapies could actually contribute to the high recurrence of these deadly tumors.

A growing body of research over the past decade, according to Seyfried, now shows the processes of radiation and chemotherapy can serve to increase the supply of glucose and glutamine, leading to conditions favorable to tumor cell survival and growth.

Furthermore, infection-fighting tumor-associated macrophages and monocytes (TAMs) that flood the brain in an effort to battle tumor cells can indirectly support tumor growth through the release of agents that lead to inflammation and the growth of blood vessels.

"What develops then is an escalating situation of biological chaos, where the intrinsic properties of TAMs to heal wounds increase the capacity of brain tumor cells to proliferate, invade, and self-renew," writes Seyfried and his co-authors, researchers Laura M. Shelton and Purna Mukherjee. "High glucose concentrations together with unrestricted glutamine availability will provide the energy necessary to drive this escalating situation."

Seyfried says this "perfect storm" of side-effects from the standard of care for glioblastoma should invite a broader discussion among researchers for potential alternative therapies. Through his past research, Seyfried has detailed the benefits of non-toxic metabolic therapies involving ketogenic diets that effectively restrict glucose-based fuels to brain tumors. By regulating glucose availability while simultaneously elevating fat-derived ketone bodies, which brain tumors cannot actively use for growth or survival, the ketogenic diet has been shown to control epileptic seizures, but there have been no human trials to test its therapeutic efficacy against brain cancer.


'/>"/>

Contact: Ed Hayward
ed.hayward@bc.edu
617-552-4826
Boston College
Source:Eurekalert

Related biology news :

1. Study points to new uses, unexpected side effects of already existing drugs
2. Stress signals link pre-existing sickness with susceptibility to bacterial infection
3. Complications early in pregnancy or in previous pregnancies adversely affect existing or subsequent pregnancies
4. Nature cover study provides new standards for reliable fisheries
5. Gold Standard/Elsevier offers timely, reliable drug pricing data, including average wholesale price
6. Meet Phannie, NISTs standard phantom for calibrating MRI machines
7. Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing
8. Researchers develop standard of care for breast cancer survivors with lymphedema
9. Stent grafts top gold standard balloon angioplasty for dialysis patients
10. Quality and safety of infant formulas, functional foods enhanced by new standards
11. U. of I. business instructional facility achieves top green standard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: